Efficacy and safety of 12 weeks of ledipasvir (inhib- itor of HCV NS5A) plus sofosbuvir (HCV nucleotide-ana- logue NS5B polymerase inhibitor) in treatment-naïve and (peg)interferon ± ribavirin-experienced hepatitis C virus genotype 6 patients

Trial Profile

Efficacy and safety of 12 weeks of ledipasvir (inhib- itor of HCV NS5A) plus sofosbuvir (HCV nucleotide-ana- logue NS5B polymerase inhibitor) in treatment-naïve and (peg)interferon ± ribavirin-experienced hepatitis C virus genotype 6 patients

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2017 New trial record
    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top